Abstract
Takeda is a research-based pharmaceutical company that has been engaged in the pharmaceutical industry for over 220 years. This report provides a full review of the company's activities together with sales forecasts for key products to 2010.
Takeda reported net sales of ¥935,213 million for the nine months ended 31st December 2005, a 7% increase over the previous year's corresponding period, supported by higher sales of in-house ethical drugs. The impact of foreign exchange fluctuations increased revenues by ¥8 billion. Operating income was up by 2% to ¥346,584 million, while net income rose by 14% to ¥281,142 million. Research and development expenditure increased by 36% to ¥116,056 million.
R&D Pipeline Overview
Takeda's pipeline is largely dominated by new indications/ formulations for its core products Actos, Takepron, Blopress and Lupron. Encouragingly for the company many of these developments are either awaiting approval or are in late stage Phase III trials. Takeda has also highlighted three novel candidate drugs as future growth drivers:
- Rozerem, an in-house developed melatonin MT1/MT2 agonist, was launched in September 2005 and is in Phase III trials in the EU and Japan for insomnia.
- Lubiprostone has been approved for chronic idiopathic constipation in the US, and has been filed for approval in this indication in Japan.
- Dimesna, currently in Phase III trials in the US, has been developed by BioNumerik Pharmaceuticals and licensed to Takeda for marketing.
Major Products Forecast to 2010
- Actos (Diabetes)
- Basen (Diabetes)
- Takepron (Gastrointestinal)
- Blopress (Cardiovascular)
- Lupron (Cardiovascular)
- Isovorin (Gastrointestinal)
- Benet (Musculoskeletal)
- Seltouch (Musculoskeletal)
Table of Contents
Latest Results
EXECUTIVE SUMMARY
- Introduction
- Financial Performance 2005
- Sales and Market Position
- Income
- Expenditure
- Capital Expenditure
- Capital Expenditure By Business Area
- R&D Expenditure
- Divisional Performance
- Sales By Business Area
- Operating Income By Business Area
- Total Assets By Business Area
- Geographic Performance
- Sales By Destination
- Sales By Origin
- Operating Income By Origin
- Ethical Sales (In-House) By Geographic Region
- Company Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Production
- Employees
- Product/R&D Overview
- Key Products
- Recent Product Launches
- Recent Product Approvals
- R&D Strategy
- Key R&D projects
- Discontinued R&D projects
- Discontinued Agreements
- Sales Forecast
- Key Products
- Conclusions
PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT
- Major Products, Therapeutic Areas and Sales
- R&D Pipeline
- Metabolic - Products
- Major Launched Products
- Actos
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Generic Competition/Lawsuits
- Competitor Products
- Sales Forecast
- Clinical Trial Results
- Basen
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Sales Forecast
- Metabolic - R&D
- Cetilistat
- Clinical Trial Results
- SYR-322
- TAK-654
- Cetilistat
- Metabolic - Summary
- Growth Potential
- Limiting Factors
- Gastrointestinal - Products
- Major Launched Products
- Takepron/Prevacid/Zoton
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Patents/Licensees
- Competitor Products
- Generic Competition
- Sales Forecast
- Altat
- Gastrointestinal - R&D
- Lubiprostone/SPI-0211
- TAK-390MR
- Ilaprazole
- Gastrointestinal - Summary
- Cardiovascular - Products
- Major Launched Products
- Blopress
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Sales Forecast
- Clinical Trial Results - Diabetic Retinopathy
- Clinical Trial Results - Heart Failure
- Adecut
- Calslot
- Cardiovascular - R&D
- Caldaret (MCC-135)
- TAK-475
- TAK-536
- Cardiovascular - Summary
- Growth Potential
- Limiting Factors
- Anticancer - Products
- Major Launched Products
- Isovorin
- Sales
- Sales Forecast
- Leuplin/Lupron/Enantone
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Lawsuits
- Patents
- Competitor Products
- Sales Forecast
- Canferon A
- Celeuk 40
- Morphine hydrochloride
- Anticancer - R&D
- Matuzumab/EMD 72000
- TAK-165
- Tavocept
- Anticancer - Summary
- Growth Potential
- Limiting Factors
- Musculoskeletal - Products
- Major Launched Products
- Benet
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Sales Forecast
- Seltouch
- Sales Forecast
- Enbrel
- Osten
- Musculoskeletal - R&D
- Febuxostat
- Clinical Trial
- TAK-715
- Febuxostat
- Musculoskeletal - Summary
- Anti-infective - Products
- Major Launched Products
- Pansporin
- Sales
- Key Markets/Indications/Launches
- Competitor Products
- Sales Forecast
- Firstcin
- Others
- Anti-infective - R&D
- R851
- TAK-187
- TAK-220
- TAK-242
- Anti-infective - Summary
- Central Nervous System - Products
- Rozerem
- Further Development
- Clinical Trial Results
- Rozerem
- Central Nervous System - R&D
- Ruboxistaurin (LY333531)
- TAK-128
- TAK-147
- TAK-428
- Central Nervous System - Summary
- Other - Products
- Dasen
- Prostal
- Solfa
- TMR
- Uprima/Ixense
- Key Markets/Indications/Formulations
- Further Development
- Other - R&D
- Hematide
- TAK-363
APPENDIX 1 - FINANCIAL PERFORMANCE
- Full Year Results 2005
APPENDIX 2 - KEY CORPORATE EVENTS
APPENDIX 3 - KEY AGREEMENTS
- 3M Pharmaceuticals
- 1st March 2005
- Abbott
- 7th March 2000
- 20th December 2005
- Affymax Inc
- 13th February 2006
- Alizyme plc
- 8th August 2003
- 30th January 2004
- Andrx Corporation
- 29th December 2003
- ASKA Pharmaceutical, KI Pharma
- 16th March 2006
- Cerexa Pharmaceuticals Inc
- 30th September 2003
- 19th October 2005
- Eli Lilly
- 25th August 1999
- 18th December 2003
- Evotec
- 6th December 2005
- IL YANG Pharmaceutical Ltd
- 9th September 2005
- Kissei Pharmaceutical Co Ltd
- 5th August 2002
- 11th May 2004
- Ligand Pharmaceuticals Inc
- 28th December 2004
- Merck KGaA
- 29th September 2005
- Mitsubishi Pharma Corporation
- 31st July 2001
- Paradigm Therapeutics Ltd
- 30th June 2005
- PPD Inc
- 13th July 2005
- Pronova Biocare AS
- 2nd November 2005
- Santhera Pharmaceuticals AG
- 3rd August 2005
- 15th December 2005
- Schering AG
- 12th October 2005
- Sucampo Pharmaceuticals Inc
- 1st November 2004
- 31st March 2005
- Teijin Limited
- 6th October 1999
- Toray Industries Ltd
- 7th April 2005
- Licensing
APPENDIX 4 - INFRASTRUCTURE
- Research and Development Facilities
- Manufacturing Facilities
APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES/JOINT VENTURES
- Subsidiaries
- Joint-Venture Companies
